Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia

Archives of General Psychiatry

Volumn 63, Issue 6, 2006, Pages 630-638

  Olincy, Ann ^a   Harris, Josette G ^a   Johnson, Lynn L ^a   Pender, Vicki ^a   Kongs, Susan ^a   Allensworth, Diana ^a   Ellis, Jamey ^a   Zerbe, Gary O ^a   Leonard, Sherry ^a,d   Stevens, Karen E ^a   Stevens, James O ^a   Martin, Laura ^a   Adler, Lawrence E ^a   Soti, Ferenc ^b   Kem, William R ^b,e   Freedman, Robert ^a,c,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e Osprey Pharmaceuticals Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(2,4 DIMETHOXY)BENZYLIDENE]ANABASEINE; ALKALOID DERIVATIVE; ARIPIPRAZOLE; FLUPHENAZINE DECANOATE; NEUROLEPTIC AGENT; NICOTINIC AGENT; NICOTINIC RECEPTOR; OLANZAPINE; PROTEIN P50; QUETIAPINE; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; ANXIETY; ARTICLE; BLUNTED AFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISORIENTATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EVOKED AUDITORY RESPONSE; FEMALE; GRANDIOSE DELUSION; GUILT; HALLUCINATION; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE;

ADULT; BENZYLIDENE COMPOUNDS; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PYRIDINES; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 33744911665     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.6.630     Document Type: Article

References (46)

1. Venables PH. Input dysfunction in schizophrenia. In: Maher BA, ed. Progress in Experimental Personality Research. Orlando, Fla: Academic Press Inc; 1967:1-64.
2. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997;94:587-592.
3. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res. 1993;10:131-144.
4. Luntz-Leybman V, Bickford PC, Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992;587:130-136.
5. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV. Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci. 1998;18:1187-1195.
6. Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha 7 and alpha 4 beta 2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol. 2001;86:3043-3055.
7. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38:22-33.
8. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 1999;73:1590-1597.
9. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. Promoter variants in the α7 nicotinic acetylcholine receptor subunit gene are associated with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry. 2002;59:1085-1090.
10. Houy E, Raux G, Thibaut F, Belmont A, Demily C, Allio G, Haouzir S, Fouldrin G, Petit M, Frebourg T. The promoter -194 C polymorphism of the nicotinic alpha 7 receptor gene has a protective effect against the P50 sensory gating deficit. Mol Psychiatry. 2004;9:320-322.
11. Dempster EL, Toulopoulou T, Wickhman H, Brannon E, McDonald C, Sham P, Murray R, Collier D. The presence of a 2bp deletion in exon 6 of the "alpha 7-like" nicotinic receptor subunit gene predicts worse performance in an episodic memory task [abstract]. Am J Med Genet B Neuropsychiatr Genet. 2004;130:3-9.
12. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC, Harkavy Friedman JM, Hampe C, Lee H, Shore D, Wynne D, Faraone SV, Tsuang MT, Cloninger CR. NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet. 1998;81:282-289.
13. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T, Williamson R, Collier D, Murray R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in southern African Bantu families. Am J Med Genet. 2000;96:196-201.
14. Stassen HH, Bridler R, Hagele S. Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet. 2000;96:173-177.
15. Liu C-M, Hwu H-G, Lin M-W, Ou-Yang W-C, Lee SF-C, Fann CSJ, Wong S-H, Hsieh S-H. Suggestive Evidence for linkage of schizophrenia to markers at chromosome 15q13-14 in Taiwanese families. Am J Med Genet. 2001;105:658-661.
16. Tsuang DW, Skol AD, Faraone SV, Bingham S, Young KA, Prabhudesai S, Haverstock SL, Mena F, Menon AS, Bisset D, Pepple J, Sauter F, Baldwin C, Weiss D, Collins J, Boehnke M, Schellenberg GD, Tsuang MT. Examination of genetic linkage of chromosome 15 to schizophrenia in a large Veterans Affairs Cooperative Study Sample. Am J Med Genet. 2001;105:662-668.
17. Xu J, Pato MT, Dalla Torre C, Medeiros H, Carvalho C, Basile VS, Bauer A, Dourado A, Valente J, Soares MJ, Macedo AA, Coelho I, Ferreira CP, Azevedo MH, Macciardi F, Kennedy JL, Pato CN. Evidence of linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am J Med Genet. 2001;105:669-674.
18. Gejman PV, Sanders AR, Badner JA. Linkage analysis of schizophrenia to chromosome 15. Am J Med Genet. 2001;105:789-793.
19. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997;42:1-5.
20. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856-1861.
21. Harris JG, Kongs S, Allensworth DA, Sullivan B, Zerbe G, Freedman R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:1378-1385.
22. Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA, Thaker GK. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl). 2004;174:334-340.
23. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry. 2004;55:850-858.
24. Depatie L, O'Driscoll G, Holahan A-L, Atkinson V, Thavundayuil J, Kin N, Lal S. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study Neuropsychopharmacology. 2002;27:1056-1070.
25. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27:479-497.
26. George TP, Vessicchio J, Termine A, Sahady D, Hear C, Pepper T, Kosten T, Wexler B. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26:75-85.
27. Kem WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S, Wildeboer K, Prokai-Tatrai K, Porter-Papke J, Soti F. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol. 2004;65:56-67.
28. de Fiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha-7/125 I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol. 1995;47:164-171.
29. Briggs CA, McKenna DG, Piattoni-Kaplan M. Human alpha-7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology. 1995;34:583-590.
30. Stokes C, Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL. The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors. Mol Pharmacol. 2004;66:14-24.
31. Mahnir V, Lin B, Prokai-Tatrai K, Kem WR. Pharmacokinetics and urinary excretion ofDMXBA(GTS-21), a compound enhancing cognition. Biopharm Drug Dispos. 1998;19:147-151.
32. Woodruff-Pak DS, Li YT, Kem WR. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 1994;645:309-317.
33. Stevens KE, Kem WR, Mahnir VM, Freedman R. Selective alpha-7 nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl). 1998;136:320-327.
34. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology. 2003;28:542-551.
35. Gold JM, Queern C, Iannone VN, Buchanan RW. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: sensitivity, reliability, and validity. Am J Psychiatry. 1999;156:1944-1950.
36. Wilk CM, Gold JM, Bartko JJ, Dickerson F, Fenton WS, Knable M, Randolph C, Buchanan RW. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry. 2002;159:838-844.
37. Kisley MA, Olincy A, Freedman R. The effect of state on sensory gating: comparison of waking, REM and non-REM sleep. Clin Neurophysiol. 2001;112:1154-1165.
38. Dunbar GC. TC-1734: a neuronal nicotinic acetylcholine receptor partial agonist that demonstrated an excellent safety/tolerability profile and cognitive enhancement in early studies in humans. Neuropsychopharmacology. 2004;29:S127.
39. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
40. Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry. 2002;159:1244-1245.
41. Koike K, Hashimoto K, Takai N, Komatsu N, Watanabe H, Nakazoto M, Okamura N, Stevens KE, Freedman R, Iyo M. Tropisetron improves deficits in auditory sensory P50 suppression in schizophrenic patients. Schizophr Res. 2005;76:67-72.
42. Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 2004;1023:54-63.
43. Adler LE, Olincy A, Cawthra E, McRae K, Harris J, Nagamoto H, Waldo MC, Hall M, Ross R, Freedman R. The varied effects of atypical medications on P50 auditory gating in schizophrenic patients. Am J Psychiatry. 2004;161:1822-1828.
44. Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl). 2003;165:386-396.
45. George TP, Serynak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995;56:344-346.
46. McEvoy JP, Freudenreich O, Wilson W. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46:125-129.